Johnson & Johnson $JNJ Shares Sold by Levin Capital Strategies L.P.

Levin Capital Strategies L.P. lessened its position in shares of Johnson & Johnson (NYSE:JNJ) by 0.4% in the second quarter, according to its most recent filing with the SEC. The firm owned 207,492 shares of the company’s stock after selling 881 shares during the quarter. Johnson & Johnson makes up approximately 3.1% of Levin Capital Strategies L.P.’s investment portfolio, making the stock its 6th largest holding. Levin Capital Strategies L.P.’s holdings in Johnson & Johnson were worth $31,694,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in JNJ. Nuveen LLC acquired a new stake in Johnson & Johnson during the 1st quarter valued at approximately $1,369,188,000. Bank of New York Mellon Corp increased its position in Johnson & Johnson by 26.4% during the 1st quarter. Bank of New York Mellon Corp now owns 23,182,464 shares of the company’s stock valued at $3,844,580,000 after purchasing an additional 4,842,582 shares during the period. Pacer Advisors Inc. increased its position in Johnson & Johnson by 1,382.0% during the 1st quarter. Pacer Advisors Inc. now owns 3,030,084 shares of the company’s stock valued at $502,509,000 after purchasing an additional 2,825,626 shares during the period. Assenagon Asset Management S.A. increased its position in Johnson & Johnson by 159.6% during the 2nd quarter. Assenagon Asset Management S.A. now owns 4,159,260 shares of the company’s stock valued at $635,327,000 after purchasing an additional 2,557,388 shares during the period. Finally, Kingstone Capital Partners Texas LLC bought a new position in shares of Johnson & Johnson during the 2nd quarter worth approximately $401,420,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have issued reports on JNJ shares. UBS Group increased their price target on Johnson & Johnson from $190.00 to $214.00 and gave the stock a “buy” rating in a report on Tuesday, October 14th. JPMorgan Chase & Co. increased their target price on Johnson & Johnson from $185.00 to $200.00 and gave the stock a “neutral” rating in a report on Tuesday, September 16th. Barclays lifted their price target on shares of Johnson & Johnson from $165.00 to $176.00 and gave the company an “equal weight” rating in a research report on Thursday, July 17th. Wall Street Zen raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a research report on Saturday, September 13th. Finally, Loop Capital set a $190.00 price target on shares of Johnson & Johnson in a research report on Wednesday, October 22nd. Three analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $199.05.

Johnson & Johnson Price Performance

Shares of NYSE:JNJ opened at $186.24 on Tuesday. The company has a current ratio of 1.07, a quick ratio of 0.80 and a debt-to-equity ratio of 0.50. The stock’s fifty day simple moving average is $183.43 and its two-hundred day simple moving average is $167.96. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $194.48. The stock has a market cap of $448.71 billion, a PE ratio of 17.98, a price-to-earnings-growth ratio of 2.19 and a beta of 0.40.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. The company had revenue of $24.02 billion for the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%. As a group, analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th will be issued a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 2.8%. The ex-dividend date of this dividend is Tuesday, November 25th. Johnson & Johnson’s payout ratio is presently 50.19%.

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the transaction, the executive vice president owned 178,013 shares of the company’s stock, valued at $31,652,491.53. The trade was a 24.08% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.16% of the stock is owned by insiders.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.